Ibere Pharmaceuticals’ $138 Million Initial Public Offering

Shearman & Sterling advised Ibere Pharmaceuticals on the deal.Ibere Pharmaceuticals, a blank check company formed for the purpose of effecting a merger in the pharmaceutical and…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

This content is for Standard 1 Year members only.
Login Join Now